PARP inhibition has also proved to be exquisitely efficient to kill tumour cells deficient in double strand break repair by homologous recombination (HR), such as cells mutated for the breast cancer early onset (BRCA) genes BRCA1 or BRCA2 [16, 17]. This evidence concerns the gene PARP1 and neoplasm.